Valuation: Insulet Corporation

Market Cap 11.75B 10.22B 9.54B 8.76B 16.51B 1,120B 16.8B 112B 44.04B 559B 44.15B 43.17B 1,843B P/E 2026 *
27.5x
P/E 2027 * 21.3x
Enterprise Value 11.82B 10.28B 9.59B 8.81B 16.61B 1,127B 16.9B 113B 44.31B 562B 44.41B 43.43B 1,854B EV / Sales 2026 *
3.56x
EV / Sales 2027 * 2.91x
Free-Float
97.63%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Insulet Corporation

1 day+2.63%
1 week+2.85%
Current month+2.63%
1 month+3.17%
3 months-3.05%
6 months-32.45%
Current year-40.30%
1 week 161.62
Extreme 161.6186
172.1
1 month 152.78
Extreme 152.78
172.92
Current year 138.79
Extreme 138.79
299.8
1 year 138.79
Extreme 138.79
354.88
3 years 125.82
Extreme 125.82
354.88
5 years 125.82
Extreme 125.82
354.88
10 years 30.69
Extreme 30.69
354.88
Manager TitleAgeSince
Chief Executive Officer 55 28/04/2025
Director of Finance/CFO 53 30/09/2025
Compliance Officer 50 01/12/2022
Director TitleAgeSince
Chairman 61 01/01/2019
Director/Board Member 61 27/07/2015
Director/Board Member 59 10/08/2017
Date Insider Type Main position Quantity % Market Cap.
7/1/26 A Free

Director

1,355 0.0019%
7/1/26 A Other

Director

0 0%
6/30/26 A Free

Director

151 0.0002%
Change 5-day change 1-year change 3-year change Capi.($)
+2.63%+2.85%-40.44%-36.03% 11.75B
+1.34%+2.52%-15.85%-0.39% 185B
+1.51%+2.92%-2.98%+2.59% 111B
-0.95%-0.89%+6.94%+61.15% 60B
+2.63%+9.46%+43.51%+59.34% 53.9B
+2.77%+7.10%-3.49%-36.65% 46.9B
+3.03%+1.94% - - 34.22B
+4.63%+19.00%+10.13%-28.48% 32.95B
+2.05%+5.04%+45.42%-5.89% 24.49B
+1.86%+6.52%+2.54%+3.17% 22.67B
Average +2.15%+4.93%+5.09%+2.09% 58.32B
Weighted average by Cap. +1.73%+3.75%+0.65%+7.16%

Financials

2026 *2027 *
Net sales 3.32B 2.89B 2.69B 2.47B 4.66B 316B 4.74B 31.76B 12.44B 158B 12.47B 12.19B 521B 3.93B 3.41B 3.19B 2.93B 5.52B 374B 5.61B 37.57B 14.71B 187B 14.75B 14.42B 616B
Net income 431M 374M 350M 321M 605M 41.07B 616M 4.12B 1.61B 20.48B 1.62B 1.58B 67.55B 565M 491M 458M 421M 793M 53.81B 807M 5.4B 2.12B 26.83B 2.12B 2.07B 88.51B
Net Debt 69.76M 60.63M 56.6M 51.96M 97.98M 6.65B 99.69M 667M 261M 3.32B 262M 256M 10.94B -340M -295M -276M -253M -478M -32.41B -486M -3.25B -1.27B -16.16B -1.28B -1.25B -53.3B
Logo Insulet Corporation
Insulet Corporation specializes in the design, manufacture and marketing of medical devices intended to improve the lives of people with insulin-dependent diabetes. In addition, the group offers non-insulin subcutaneous drug delivery systems used in several therapeutic areas. Net sales break down by family of products as follows: - Insulin pump therapy systems (98.7%): continuous insulin management and delivery systems (Omnipod® and Omnipod DASH® brands) and automated insulin administration systems (Omnipod® 5 brand); - non-insulin drug administration systems (1.3%): in particular pre-filled syringes for the Neulasta® Onpro® kit (intended for the treatment of neutropenia in patients treated with chemotherapy). At the end of 2025, the group had 2 production sites located in the United States and in China. The United States account for 72.2% of net sales.
Employees
5,400
Date Price Change Volume
03/08/26 $169.70 +2.63% 1,408,011
31/07/26 $165.35 -0.20% 1,314,052
30/07/26 $165.68 -2.90% 1,215,698
29/07/26 $170.62 +1.88% 1,126,164
28/07/26 $167.47 +1.50% 1,296,134
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
25
Last Close Price
169.70USD
Average target price
235.54USD
Spread / Average Target
+38.80%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PODD Stock